Cite
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation.
MLA
Martino, Massimo, et al. “Correction to: Effectiveness of Biosimilar Pegfilgrastim in Patients with Multiple Myeloma after High‑dose Melphalan and Autologous Stem Cell Transplantation.” Annals of Hematology, vol. 102, no. 8, Aug. 2023, pp. 2297–98. EBSCOhost, https://doi.org/10.1007/s00277-023-05323-1.
APA
Martino, M., Gori, M., Porto, G., Pellicano, M., Santoro, L., Verduci, C., Canale, F. A., Loteta, B., Moscato, T., Alati, C., Ieracitano, M. C., Cuzzocrea, A., Altomonte, M., Florenzano, M. T., Morabito, A., Irrera, G., Naso, V., Pugliese, M., Console, G., & Ferreri, A. (2023). Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation. Annals of Hematology, 102(8), 2297–2298. https://doi.org/10.1007/s00277-023-05323-1
Chicago
Martino, Massimo, Mercedes Gori, Gaetana Porto, Maria Pellicano, Ludovica Santoro, Chiara Verduci, Filippo Antonio Canale, et al. 2023. “Correction to: Effectiveness of Biosimilar Pegfilgrastim in Patients with Multiple Myeloma after High‑dose Melphalan and Autologous Stem Cell Transplantation.” Annals of Hematology 102 (8): 2297–98. doi:10.1007/s00277-023-05323-1.